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ABSTRACT   
 
Introduction: We investigated the diagnostic and classificatory performance of multivariate 
combinations of 6 gold-standard core and novel pathophysiological cerebrospinal fluid (CSF) 
candidate biomarkers of neurodegeneration-related mechanisms.  
Methods: Core Alzheimer’s disease (AD) CSF biomarkers included the 42-amino acid-long 
amyloid beta (Aβ) peptide (Aβ1-42), total tau (t-tau), and phosphorylated tau (p-tau) proteins. Novel 
candidate pathophysiological biomarkers in development included the neurofilament light chain 
(NFL) protein, neurogranin, and YKL-40. The diagnostic and classificatory performances of all 
possible combinations of the six candidate pathophysiological CSF biomarkers were compared 
among individuals with mild cognitive impairment (MCI) (n=41), AD dementia (ADD) (n=35), 
frontotemporal dementia (FTD) (n=9), and cognitively healthy controls (HC) (n=21).  
Results: We identified the combinations that ranked in the top 10 according to diagnostic 
accuracy in the classification of HC from MCI, HC from ADD, HC from FTD, MCI from ADD, 
and ADD from FTD. Notably, novel biomarkers alone or in combination appeared in the top 10 in 
all comparisons. The single biomarkers or biomarker combinations generating the best AUROCs 
were: [Aβ1-42+p-tau+NFL] for distinguishing between ADD and HC (AUROC=0.86), t-tau for 
distinguishing between ADD and FTD (AUROC=0.82), t-tau for distinguishing between FTD and 
HC (AUROC=0.78), [Aβ1-42+NFL] for distinguishing between ADD and MCI (AUROC = 0.71), 
and Aβ1-42 for distinguishing between MCI and HC (AUROC=0.62).  
Discussion: The biomarker combination signature [Aβ1-42+p-tau+NFL] differentiated ADD 
patients from HC with good diagnostic accuracy. The diagnostic performances of CSF t-tau in 
distinguishing FTD patients from ADD and HC were good and fair, respectively. CSF Aβ1-42+NFL 
differentiated ADD from MCI with fair diagnostic accuracy. CSF Aβ1-42 discriminated MCI 
subjects from HC with poor diagnostic accuracy.  
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1. INTRODUCTION  
Polygenic Alzheimer’s disease (AD) is a pathophysiologically complex and clinically 
heterogeneous neurodegenerative disease [1]. The extracellular deposition of accumulated amyloid 
beta (Aβ) peptide into amyloid plaques and the intracellular accumulation of neurofibrillary tangles 
are considered pathophysiological hallmarks of AD. Cerebrospinal fluid (CSF) concentrations of 
the 42-amino acid-long Aβ peptide (Aβ1-42), total tau (t-tau), and hyperphosphorylated tau (p-tau) 
proteins, which represent pathophysiological biomarkers of amyloid pathology, cortical axonal 
degeneration, and tangle pathology, respectively, have been validated as core, feasible [2,3] 
biomarkers of AD pathophysiology [4]. Recently emerging evidence highlighted the presence of 
additional molecular pathophysiological pathways – such as axonal disintegration [5], synaptic 
pathology [6], innate immune response and neuroinflammation [5,7,8] – throughout the different 
stages of AD [1,7,9–11].  
A growing number of discovery stage biomarker studies have been conducted aimed to identify, 
develop and validate additional molecular pathophysiological pathways in AD, including different 
target populations, such as AD dementia (ADD), mild cognitive impairment (MCI) due to AD (also 
called prodromal AD), as well as the asymptomatic preclinical stages [12–15]. Among those, CSF 
neurofilament light chain (NFL) [5], neurogranin [6], and YKL-40 [5,8] proteins have reached an 
advanced clinical validation stage and represent innovative pathophysiological candidate 
biomarkers which may complement and optimize the biomarker-guided in vivo detection of AD-
associated pathophysiological pathways (for identifying treatable mechanisms for targeted therapy 
development). In other relevant contexts of use (CoU), they may complement and enhance the 
developing biomarker-guided detection and diagnostic algorithm to identify AD patients at various 
disease stages in the clinic, as established in recently refined international diagnostic criteria [16], 
and for clinical trials (as biomarker stratified or enriched target populations). 
Specifically, NFL is a primary structural component of the neuronal cytoskeleton [17] and a 
marker of large-caliber axonal disintegration [17,18]. Neurogranin is a postsynaptic protein 
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predominant in dendritic spines of neurons within associative cortical areas, and is involved in 
modulating synaptic transmission and plasticity mechanisms [19]. Finally, YKL-40, a glycoprotein 
expressed in both microglia and astroglia in the central nervous system, represents a relevant 
candidate biomarker of neuroinflammation and/or astrocytic/microglial activation [8]. Interestingly, 
a recent meta-analysis showed that both NFL and YKL-40 proteins are promising biomarkers useful 
to differentiate AD patients from cognitively healthy control (HC) individuals [5]; furthermore, 
increased CSF neurogranin concentrations were found to be related to AD-characteristic 
pathophysiology [6,20].  
Only a limited number of available studies have assessed the diagnostic accuracy of CSF core 
AD biomarkers in combination with two out of these three novel mechanistic biomarkers of AD 
pathophysiology [20–22]. To our knowledge, no previous study examined the CSF concentrations 
of the three biomarkers in combination with the core AD biomarkers in cohorts of patients with AD 
or other primary neurodegenerative diseases.  
To our knowledge for the first time, we assessed the diagnostic and classificatory performance of 
three novel CSF pathophysiological biomarkers at advanced validation stages – NFL, neurogranin, 
and YKL-40 – as single biomarkers or in combination with the traditional core biomarkers, using an 
international academic expert multicenter cohort of individuals with cognitive impairment and 
dementia. We explored the diagnostic performance in differentiating HC individuals from subjects 
with MCI, patients with ADD, and patients with frontotemporal dementia (FTD). In addition, we 
determined the diagnostic accuracy in discriminating MCI subjects from ADD patients and ADD 
from FTD cases. For each of the above-mentioned group comparisons, we implemented exhaustive 
searches to assess which combination of the panel of 6 biomarkers – both novel and core 
biomarkers – provided the best classification performance. 
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2. METHODS 
2.1. Study participants  
This multicenter cross-sectional study was conducted retrospectively in a convenience series 
from three independent European academic expert memory clinics. A total of 135 participants were 
examined; out of these, 27 were excluded due to missing data regarding one or more CSF 
biomarkers and the remaining 108 were included in the present study. Specifically, 35 participants 
were recruited from the Institute for Memory and Alzheimer’s Disease (Institut de la Mémoire et de 
la Maladie d’Alzheimer, IM2A) – a sub-cohort of the Alzheimer Precision Medicine Initiative 
Cohort Program (APMI-CP) [23] – at the Pitié-Salpêtrière University Hospital in Paris (France), 57 
from the German Center for Neurodegenerative Diseases (DZNE) in Rostock (Germany), and 16 
from the Institute of Neuroscience and Physiology at Sahlgrenska University Hospital in Mölndal 
(Sweden).  
The study complied with the tenets of the Declaration of Helsinki and was approved by the local 
Ethical Committees at each participating university center. All participants or their representatives 
gave written informed consent for the use of their clinical data for research purposes.  
 
2.2. Clinical diagnoses  
The clinical diagnosis of ADD was performed according to the National Institute of Neurological 
and Communicative Disorders and Stroke-Alzheimer’s Disease and Related Disorders Association 
(NINCDS-ADRDA) consensus criteria [24]. The clinical diagnosis of MCI was based on the MCI 
core clinical criteria [25]. The clinical diagnosis of FTD was performed according to the consensus 
on clinical diagnostic criteria published in 1998 [26]. Cognitively HC were individuals who: I) 
volunteered for lumbar puncture, II) showed a negative of neurological or psychiatric diseases, and 
III) had a Mini-Mental State Examination (MMSE) scores between 27 and 30. Of the 23 cognitively 
HC, two individuals from the Gothenburg cohort showed CSF t-tau concentrations higher than the 
established cut-off value. Being asymptomatic-at-risk of AD [16] or preclinical AD [27], they were 
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excluded from additional analyses. The group clinically defined as MCI included 41 participants 
[25]. Finally, 35 ADD [24] and 9 FTD [26] patients were included.  
 
2.3. CSF sampling 
A diagnostic lumbar puncture was performed in all participants. All CSF samples included in the 
three study cohorts were collected in polypropylene tubes, centrifuged at 1000 g for 10 minutes at 
+4°C (samples collected at the IM2A in Paris), 1500 g for 10 minutes at +4°C (samples collected at 
the DZNE in Rostock), 1800 g for 10 minutes at +4°C (samples collected at the Clinical 
Neurochemistry Laboratory in Mölndal). The collected supernatant was stored at –80°C pending 
biochemical analysis.  
 
2.4. Immunoassays for CSF core biomarkers 
For the Paris cohort, CSF analyses of the biomarkers Aβ1-42, t-tau, and p-tau were performed at 
the Laboratory of Biochemistry, Unit of Biochemistry of Neurometabolic diseases, Pitié-Salpêtrière 
University Hospital of Paris. For the Rostock cohort, CSF analyses were conducted in two different 
units: the Institute of Clinical Chemistry and Laboratory Medicine, Rostock University Medical 
Centre, as of June 2012, and the Laboratory of Neurochemistry, Department of Neurology, 
Göttingen University Medical Center, before June 2012. For the Gothenburg cohort, CSF analyses 
took place at the Clinical Neurochemistry Laboratory at the Sahlgrenska University Hospital, 
Mölndal. CSF Aβ1-42, t-tau, and tau phosphorylated at threonine 181 (p-tau181) concentrations were 
measured using established sandwich ELISA methods, INNOTEST β-AMYLOID(1-42) [28], 
INNOTEST hTAU-Ag [29], and INNOTEST Phospho-Tau[181P] [30] (Fujirebio Europe NV, 
Gent, Belgium), respectively. All analyses were performed by experienced laboratory technicians 
blinded to clinical information. All laboratories participate in the Alzheimer’s Association Quality 
Control Program for CSF biomarkers and the Global Biomarker Standardization Consortium (ref: 
Carrillo MC et al., Alzheimers Dement. 2013 Mar;9(2):137-40). Pathologic CSF biomarker 
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concentrations were defined based on reference threshold cut-off values currently established in 
each memory clinic: at IM2A in Paris, Aβ1-42 < 500 pg/mL, t-tau > 450 pg/mL, p-tau181 > 60 pg/mL; 
at DZNE in Rostock, Aβ1-42 < 567 pg/mL, t-tau > 512 pg/mL, p-tau181 > 66 pg/mL (for the CSF 
samples measured before June 2012) and Aβ1-42 < 450 pg/mL, t-tau > 450 pg/mL, p-tau181 > 62 
pg/mL (for the CSF samples measured after June 2012); at Clinical Neurochemistry Laboratory in 
Mölndal, Aβ1-42 < 550 pg/mL, t-tau > 400 pg/mL, p-tau181 > 80 pg/mL.  
 
2.5. Immunoassays for CSF NFL, neurogranin, and YKL-40 
All CSF NFL, neurogranin and YKL-40 analyses were performed at the studies central 
laboratory, the Clinical Neurochemistry Laboratory at the Sahlgrenska University Hospital, 
Mölndal, Sweden. CSF NFL protein concentrations were measured with a sensitive sandwich 
ELISA method (NF-light ELISA kit; UmanDiagnostics AB, Umeå, Sweden), as described by the 
manufacturer. The lower limit of quantification for this assay was 50 ng/L; CSF neurogranin 
analyses were performed using a previously described analytical methodology [31]. In brief, CSF 
neurogranin was measured using an in-house ELISA assay based on the monoclonal antibody Ng7 
(epitope including amino acids 52–65 on neurogranin) for capture, a polyclonal neurogranin anti-
rabbit antibody (ab23570; Upstate Biotechnology, Lake Placid, NY, USA) for detection, and full-
length neurogranin protein as calibrator. The detection limit of the assay was 125 pg/mL. The intra- 
and inter-assay coefficients of variations were 6% and 9%, respectively. CSF YKL-40 protein 
concentrations were measured using a commercial available ELISA kit (R&D Systems, 
Minneapolis, MN, US), according to manufacturer instructions. Intra-assay coefficients of variation 
were below 10%. All analyses were performed on one occasion in a randomized fashion by board-
certified laboratory personnel blinded to clinical data to avoid bias.  
 
2.6. Statistical Analysis  
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The associations between participant groups and sex as well as age were assessed with Fisher’s 
exact test and nonparametric Kruskal-Wallis (KW) tests, respectively. Before further analysis, both 
core and novel candidate biomarker values were adjusted for age, sex, and site using nonparametric 
regression. This step allowed age-, sex-, and site- independent assessment of the discriminatory 
performance of all biomarkers while foregoing assumptions of normality. Bivariate associations 
between all biomarkers in the entire study cohort were explored with Spearman’s correlation 
coefficients with correction for multiple comparisons. Additionally, multivariate associations (i.e. 
independent contributions of any five biomarkers to the variability of the remaining novel 
biomarker) in the entire study cohort were examined by employing NFL, neurogranin, and YKL-40 
as dependent variables in three distinct multivariate regression models in which all remaining 
biomarkers were used as regressors. 
We conducted group-wise comparisons of biomarker values through nonparametric KW tests 
followed by pairwise post-hoc comparison (Conover's-test for multiple comparisons) whenever the 
result of the KW test was statistically significant (P < 0.05). Results of post-hoc testing were 
corrected for multiple comparisons using a False Discovery Rate (FDR) procedure (α = 0.05).  
We then evaluated the potential diagnostic and classificatory performance of all possible 
combinations of both traditional core and novel biomarkers (from any single biomarker to a total of 
6 biomarkers) using logistic regression within a 10-fold cross validation (10-fold CV) approach in 
the following a priori comparisons: HC versus MCI, HC versus ADD, HC versus FTD, MCI versus 
ADD, and ADD versus FTD. In this analysis, age-, sex-, and site- adjusted values of all biomarkers 
employed in any particular combination were entered as predictors and the diagnostic group was 
entered as the dependent variable. After model fitting, we calculated the area under the receiver 
operating characteristic (AUROC) curve and its associated confidence intervals using a bootstrap 
procedure (100000 bootstraps) [32] by pooling predictions computed on the test sets from each 
train-test split in the 10-fold CV procedure. For each combination of biomarkers, the ability to 
correctly allocate participants to diagnostic groups was classified as follows: “excellent” (AUROC 
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0.90-1.00), “good” (AUROC 0.80-0.89), “fair” (AUROC 0.70-0.79), poor (AUROC 0.60-0.69), or 
“fail”/no discriminatory capacity (AUROC 0.50-0.59) [33]. 
All statistical analyses were performed in the R statistical environment version 3.2.3 (available at 
https://www.R-project.org/) under a Linux environment using the nonparametric kernel smoothing 
methods for mixed data types package (np package) (available at 
https://www.jstatsoft.org/article/view/v027i05), partial ROC (pROC) package, and the pairwise 
multiple comparison of mean ranks (PMCMR) package (available at https://cran.r-
project.org/web/packages/PMCMR/vignettes/PMCMR.pdf) [32,34]. Two-tailed P values < 0.05 
were considered statistically significant.  
 
3. RESULTS 
3.1. CSF biomarkers concentrations  
Table 1 summarizes the concentrations of all analytes, both core and novel candidate 
biomarkers, combined with demographic and clinical data of the population. KW tests showed a 
significant effect of group on age (P < 0.001), MMSE (P = 0.002), and all CSF biomarkers (Aβ1-42, 
P < 0.001; p-tau, P < 0.001; t-tau, P < 0.001; NFL, P = 0.004; neurogranin, P = 0.002; YKL-40, P= 
0.0156). Post-hoc testing determined that cognitively HC were significantly younger than MCI 
subjects, AD, and FTD patients. MMSE scores were significantly lower in AD compared with HC 
and MCI. CSF Aβ1-42 concentrations were significantly lower in ADD versus HC, MCI, and FTD 
(P < 0.001, P < 0.001, P = 0.003, respectively) and in MCI versus HC (P = 0.029). Compared with 
HC, both CSF t-tau and p-tau concentrations were significantly higher in MCI (P < 0.001 and P = 
0.002, respectively), ADD (P = 0.003 and P = 0.007, respectively), and FTD (P = 0.001 and P = 
0.014, respectively) (Table 1). CSF NFL concentrations were significantly higher in ADD versus 
HC and MCI (P = 0.004 and P = 0.013, respectively) (Figure 1A). CSF neurogranin concentrations 
were significantly higher in ADD versus HC and FTD (P = 0.004 for both comparisons) (Figure 
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1B). YKL-40 concentrations were significantly higher in ADD versus HC and FTD (P = 0.032 and 
P = 0.049, respectively) (Figure 1C). 
 
3.2. Diagnostic accuracies of CSF biomarkers 
Table 2 summarizes – in descending order in terms of AUROC values – the 10 biomarker 
combinations which yielded the best diagnostic accuracies in distinguishing HC from MCI, ADD, 
FTD, as well as MCI from ADD, and ADD from FTD. In particular, the combination [Aβ1-42+p-
tau+NFL] differentiated ADD from HC with an AUROC of 0.86 (95% CI, 0.83–0.89). T-tau and 
[Aβ1-42+p-tau+YKL-40] discriminated ADD from FTD with an AUROC of 0.82 (95% CI, 0.78–
0.86) and 0.81 (95% CI, 0.77–0.85), respectively. T-tau and [p-tau+YKL-40] distinguished FTD 
from HC with an AUROC of 0.78 (95% CI, 0.73–0.83) and 0.73 (95% CI, 0.67–0.79), respectively. 
The combination [Aβ1-42+NFL] differentiated ADD from MCI with an AUROC of 0.71 (95% CI, 
0.67–0.75). Aβ1-42 and [Aβ1-42+YKL-40] discriminated MCI from HC with an AUROC of 0.62 
(95% CI, 0.58–0.67) and 0.61 (95% CI, 0.57–0.66), respectively (Table 2).  
 
3.3. Correlations between all CSF biomarkers in the whole study cohort 
Table 3 shows the correlation matrix between all biomarkers, in the whole study cohort, after 
correction for multiple comparisons. All biomarkers were significantly correlated with each other, 
except for the Aβ1-42 peptide, which was only correlated with p-tau and t-tau proteins. In the 
multivariate regression models, YKL-40 resulted to be a significant contributor (P < 0.001) in 
explaining the variability in NFL; t-tau (P < 0.001) contributed significantly to neurogranin 
variability; p-tau (P = 0.002), NFL (P = 0.0175), and neurogranin (P = 0.0250) contributed 
significantly to YKL-40 variability.  
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DISCUSSION 
Our results showed that CSF NFL concentrations were significantly higher in ADD patients 
versus HC and MCI subjects. These outcomes are consistent with a recent analysis reporting the 
association between CSF NFL concentration and cognitive impairment [35]. Both CSF neurogranin 
and YKL-40 concentrations were significantly higher in ADD versus HC, thus confirming earlier 
reported data [6,8]. Furthermore, we demonstrated significantly higher concentrations of CSF 
neurogranin in ADD compared with FTD; this finding corroborates previous data indicating a 
selective increase in CSF neurogranin in individuals showing AD pathophysiology [6]. We also 
found higher concentrations of CSF YKL-40 in ADD compared with FTD. In this regard, a non-AD 
specific increase of CSF YKL-40 versus HC was described [8,20,36,37]. Prior investigations 
reported both higher and similar CSF YKL-40 concentrations in FTD compared to ADD patients 
[8,20]. As expected, CSF Aβ1-42 concentrations were significantly lower in ADD patients compared 
with HC, MCI, and FTD as well as in MCI compared to HC individuals [1,4,5]; moreover, 
compared with HC, both CSF t-tau and p-tau concentrations were significantly increased in MCI, 
ADD, and FTD patients [1,4,5]. In bivariate correlation analyses, both novel and core biomarkers 
were significantly associated with each other, with the exception of the Aβ1-42 peptide, which was 
only correlated with p-tau and t-tau proteins. In particular, the association was strong among 
neurogranin, t-tau, and p-tau and moderate among NFL, neurogranin, and YKL-40. In addition, 
NFL and YKL-40 showed a moderate correlation with both t-tau and p-tau. Notably, in the 
multivariate regression models, CSF YKL-40 concentrations resulted to be a significant 
independent contributor in explaining the variability in NFL; this is in agreement with earlier data 
showing that CSF YKL-40 values are positively related to NFL in both asymptomatic preclinical 
AD and PD subjects [38]. Therefore, CSF NFL concentrations contributed significantly to 
explaining CSF YKL-40 variability. Furthermore, we disclosed that CSF t-tau contributed 
significantly to explaining the variation of CSF neurogranin concentrations; such a finding was also 
documented in two other studies on AD [20,22]. Moreover, in accordance with our results, previous 
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investigations reported that CSF NFL, neurogranin, and YKL-40 demonstrated more robust 
associations with CSF tau proteins than with CSF Aβ1-42 [6,8,39,40]. Finally, separate studies 
highlighted an association of CSF NFL with both YKL-40 [8,38,41] and neurogranin [6,8,39]. 
Interestingly, a possible link between neurogranin and YKL-40 has not yet been examined. 
To our knowledge, this is the first study scrutinizing the diagnostic contribution and added value 
of the novel pathophysiological CSF candidate biomarker panel – NFL, neurogranin, and YKL-40 – 
both as single markers and in combination – in the biomarker-guided diagnosis of AD [5,20], 
following the application of a diagnostic workflow for the selection of the best performing 
biomarker combinations (Figure 2). In particular, we describe – for the first time in a multicenter 
cohort of participants with cognitive impairment – the correlations between the three biomarkers 
and explore their association with tau protein-dependent pathophysiological mechanisms. 
Importantly, any combination of biomarkers (standard core or novel) differentiated HC from 
MCI with a poor diagnostic accuracy. When distinguishing HC from ADD, both CSF NFL and 
neurogranin appeared within the top 10 ranked biomarker combinations in conjunction with 
standard core biomarkers, and all combinations delivered good diagnostic accuracy, which was 
comparable to the one delivered by e.g. Aβ1-42 alone. When distinguishing HC from FTD, YKL-40 
combined with p-tau and t-tau delivered fair diagnostic accuracy, which was comparable to the one 
delivered by e.g. t-tau alone. When distinguishing MCI from ADD, various combinations of all 
three novel biomarkers with the core biomarkers delivered fair diagnostic accuracy, which was 
comparable to the one afforded by e.g. t-tau alone or t-tau and Aβ1-42. When distinguishing ADD 
from FTD, various combinations of the 3 novel candidate biomarkers with the standard core ones 
delivered good diagnostic accuracy that was, however, not superior to the diagnostic accuracy 
achieved by the core biomarkers alone (Aβ1-42, p-tau, t-tau). In summary, as mentioned above, no 
combination including the 3 novel candidate biomarkers was superior to e.g. Aβ1-42 in 
distinguishing HC from MCI and ADD, neither to t-tau in differentiating HC from FTD, nor to Aβ1-
42, p-tau, and t-tau in discriminating ADD from FTD as well as MCI from ADD.  
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The introduction of innovative pathophysiological CSF biomarkers, which reflect distinct 
biochemical and molecular mechanisms – axonal disintegration, synaptic pathology, innate immune 
response and neuroinflammation –meaningfully complements the pathways associated with 
polygenic AD. It will further complement the evolving biomarker-guided diagnostic workflow, 
such as the diagnostic model proposed by the International Working Group (IWG) [16]. Here, and 
at any stage of the disease, the diagnosis of “typical AD” relies on the presence of traditional core 
pathophysiological biomarker signature: low CSF Aβ1-42 concentrations and elevated CSF t-tau (or 
p-tau) concentrations or positivity to amyloid-positron emission tomography (PET) (i.e., high 
retention of amyloid tracer) [16]. Recently, Ewers and colleagues (2015) [42], in a large-scale 
international multicenter study tested the diagnostic and classificatory performance of standard CSF 
core biomarkers to discriminate ADD from other clinically relevant dementia disorders. They 
reported that CSF Aβ1-42 alone or combined with the CSF p-tau181/Aβ1-42 ratio differentiated ADD 
from FTD but exhibited a large overlap between ADD and other dementia disorders. This outcome, 
therefore, highlighted the limited diagnostic usefulness of the exclusive use of standard core 
biomarkers in the classification of ADD from a variety of other relevant neurodegenerative diseases 
and dementia disorders. We hypothesized, that the integration of complementary pathophysiological 
biomarker candidates covering additional key AD mechanisms will likely result in an incremental 
performance optimization for the detection, diagnosis and differential diagnosis of primary 
neurodegenerative diseases and dementia disorders, including AD and FTD.  
The combined use of all six mostly validated and matured candidate biomarkers here, allows the 
for an extension of the proposed “agnostic nomenclature”, the “A/T/N” scheme, an unbiased 
biomarker-driven model of stratification, as recently reported by Jack and colleagues (2016) [43]. 
This model comprises three binary (positive/negative) categories: “A” referring to an amyloid 
biomarker (CSF Aβ1-42 or amyloid-PET), “T” to a tau pathology biomarker (CSF p-tau or tau-PET), 
and “N” to a quantitative or topographic biomarker of neurodegeneration or neuronal injury (CSF t-
tau, 18F-Fluorodeoxyglucose (FDG)-PET, or structural magnetic resonance imaging (MRI)). Owing 
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to its agnostic and unbiased nature, the use of this dissection model is potentially appropriate in any 
context of diagnostic criteria [9]. Here, we aim at proposing additional candidates to logically 
expand the A/T/N biomarker panel in integrating (I) biomarkers of other existing 
pathophysiological mechanisms – such as axonal disintegration, synaptic pathology, and 
neuroinflammation – characterizing the dimensional spectrum of age-related 
proteinopathies/neurodegenerative diseases and (II) genetic/epigenetic factors [44]. This descriptive 
approach will enable to look as focussed but as complimentary as possible at any relevant 
pathophysiological alterations underlying older cognitively impaired individuals in an agnostic 
fashion. This will allow to identify subsets of AD patients with distinct pathophysiological patterns, 
as requested by the emerging theoretical concepts of precision medicine and precision neurology 
[9,23,45]. Additional analyses using a composite array including the three presented innovative 
biomarkers are necessary in order to achieve a more accurate stratification of patients’ cohorts 
according to different AD-related pathophysiological pathways [8,9,23,45]. This strategy might 
help provide the basis to accelerate the development of effective targeted therapeutic approaches, 
namely “molecularly” or biomarker-guided targeted or customized therapies [9,23,45]. As a result, 
focussed therapeutic interventions are expected to be developed for the treatment of the individual 
patient’s biological makeup, with expected higher efficacy.  
An intriguing feature of the results that warrants additional studies is the moderate to strong 
correlations between biomarkers that should represent rather distinct pathological processes. This 
could either mean that their concentrations are influenced by common factors, such as CSF 
turnover, or that the pathological processes they are thought to represent often occur in synchrony. 
The latter hypothesis would fit well with the recently proposed revised model in which AD 
pathogenesis is described as a long, complex cellular phase consisting of feedback and feedforward 
responses of astrocytes, microglia, and vasculature to A, tau and potentially other pathologies (ref: 
De Strooper B and Karran E. Cell. 2016 Feb 11;164(4):603-15).    
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There are some limitations of our study. As our dataset did not include longitudinal follow-up, it 
was not possible to distinguish between stable MCI and MCI subjects progressing to dementia. 
Furthermore, more extensive psychometric evaluations were not available, thus precluding the 
analysis of the concentrations of the novel biomarkers in relation to different cognitive domains. 
Moreover, the quantification of the standard core CSF AD biomarkers was not performed in one 
central reference laboratory and, while we controlled for center effects – as well as for age and sex 
– in the statistical analysis, additional inter-laboratory variability could not be fully controlled. 
Longitudinal studies need to be designed to evaluate the potential role of the three novel biomarker 
candidates – both alone and in combination – in the prediction of progression from prodromal MCI 
to the dementia stage. In addition, since the sample size of our cohort was relatively small, 
especially in the FTD group, it was not possible to evaluate in detail the diagnostic accuracy of the 
three emerging CSF biomarkers in differentiating AD from non-AD neurodegenerative diseases. 
Therefore, future studies should be directed towards increasing the statistical power by collecting 
larger, multisite cohorts.  
In summary, we found that none of the multivariate combinations performed superior to the 
gold-standard core, feasible biomarkers in the classification of HC from MCI, HC from ADD, HC 
from FTD, MCI from ADD, and ADD from FTD. Future independent validation of our findings in 
larger multicenter cohorts, including sufficient numbers of patients with other neurodegenerative 
diseases, is needed to confirm and expand on our data. Particularly, longitudinal analyses are 
warranted in asymptomatic preclinical at risk for AD individuals to investigate whether components 
of the biomarker panel may be valuable predictors (surrogates) of disease progression and 
conversion to clinical milestones, such as prodromal MCI and dementia. To this aim, we are 
currently in the process of conducting these longitudinal studies using a unique large-scale a 
monocentric cohort (INSIGHT-preAD) – within the framework of the APMI and as part of the 
APMI-CP [23] – including amyloid-PET stratified preclinical asymptomatic individuals at risk for 
AD in order to elucidate the temporal dynamics of all six, and more, pathophysiological biomarkers 
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and test their potential correlation with genomics and multi-modal neuroimaging and EEG data, 
throughout disease progression commencing at the preclinical stage. The ultimate aim is to identify 
disease trajectories through space and time using integrated disease modelling (IDM) that may 
serve as more precise guideposts for detecting the disease at earliest possible preclinical stages as 
well as initiating treatment interventions of distinct pathophysiological mechanisms through the 
biomarker-guided targeted therapy trials of the future.  
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Table 1. Summary of the demographic, clinical, and biomarker data of the population  
 HC MCI ADD FTD 
Sex, n (F/M) 21 (13/8) 41 (14/27) 35 (24/11) 9 (5/4) 
Age at LP (y) 64 (59-59) 72 (65-75)e 73 (68-76)e 73 (70-74)a 
MMSE at LP (/30) 30 (29-30) 26 (24-28) 23 (19-26)a,b 23 (19-26) 
CSF neurogranin (pg/mL) 180 (125-273) 331 (215-484) 468 (300-692)a,d 125 (125-192) 
CSF NFL (pg/mL) 609 (516-773) 1046 (793-1767) 1483 (1180-1844)a,b 1022 (693-1435) 
CSF YKL-40 (ng/mL) 98 (90-110) 128 (98-184) 146 (119-177)a,d 114 (98-120) 
CSF Aβ1-42 (pg/mL) 910 (785-996) 540 (411-911)
a 424 (374-503)d,e,f 652 (530-823) 
CSF t-tau (pg/mL) 201 (127-243) 261 (189-452) 496 (360-764)b,d,e 208 (161-340) 
CSF p-tau (pg/mL) 44 (35-48) 60 (44-80) 83 (64-126)a,b,d 31 (27-53) 
Abbreviations: Aβ1-42, 42-amino acid-long amyloid beta peptide; ADD, Alzheimer’s disease dementia; CSF, cerebrospinal fluid; HC, cognitively healthy controls; 
F, female; FTD, frontotemporal dementia; LP, lumbar puncture; M, male; MCI, mild cognitive impairment; MMSE, mini-mental state examination; NFL, 
neurofilament light chain protein; p-tau, hyperphosphorylated tau; t-tau, total tau.  
NOTE. All data are median values with 25th and 75th quartiles, except for n.  
P values for MMSE, neurogranin, NFL, YKL-40, Aβ1-42, t-tau, p-tau were adjusted for age, sex and site.  
aP< 0.05 vs HC; bP< 0.05 vs MCI; cP< 0.05 vs AD; dP< 0.05 vs FTD.  
eP< 0.001 vs HC; fP< 0.001 vs MCI.  
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Table 2. The first 10 best ranked diagnostic accuracies of the CSF core and novel pathophysiological biomarkers, alone or in combination, in differentiating 
HC from MCI, HC from ADD, HC from FTD, MCI from ADD, and ADD from FTD are reported. Results are shown starting from the highest to the lowest 
AUROC value for every group comparison.  
  
Best 10 predictors  Group comparisons AUROC AUROC C.I. low AUROC C.I. high 
Aβ1-42 HC MCI 62.37 57.95 66.78 
Aβ1-42 + YKL-40 HC MCI 61.54 57.00 66.08 
YKL-40  HC MCI 60.93 56.45 65.41 
Aβ1-42 + NFL HC MCI 60.28 55.88 64.68 
Aβ1-42 + t-tau + YKL-40 HC MCI 60.15 55.63 64.67 
Aβ1-42 + NFL + YKL-40 HC MCI 60.03 55.50 64.56 
Aβ1-42 + t-tau  HC MCI 59.89 55.42 64.36 
Aβ1-42 + neurogranin + YKL-40 HC MCI 59.08 54.46 63.69 
Neurogranin + YKL-40 HC MCI 58.55 53.95 63.14 
Neurogranin HC MCI 58.46 53.97 62.95 
 
Aβ1-42 + p-tau + NFL HC ADD 86.41 83.48 89.35 
Aβ1-42 + p-tau + t-tau + NFL HC ADD 86.18 83.21 89.15 
Aβ1-42 HC ADD 86.12 82.85 89.39 
t-tau + NFL HC ADD 85.83 82.90 88.76 
Aβ1-42 + neurogranin + NFL HC ADD 85.69 82.52 88.86 
Aβ1-42 + p-tau + NFL HC ADD 85.50 82.46 88.53 
Aβ1-42 + t-tau HC ADD 85.03 81.85 88.21 
Aβ1-42 + t-tau + neurogranin + NFL HC ADD 84.33 81.10 87.56 
Aβ1-42 + p-tau + t-tau HC ADD 84.21 80.96 87.45 
p-tau + t-tau + NFL HC ADD 84.10 80.96 87.24 
 
t-tau HC FTD 77.90 72.61 83.20 
p-tau + YKL-40 HC FTD 72.65 66.69 78.60 
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t-tau + YKL40 HC FTD 68.85 62.76 74.93 
p-tau + neurogranin + YKL-40 HC FTD 64.70 57.97 71.43 
p-tau HC FTD 62.84 56.32 69.37 
Aβ1-42 + t-tau + YKL-40 HC FTD 61.83 54.98 68.67 
p-tau + neurogranin HC FTD 61.35 54.39 68.32 
Aβ1-42 + p-tau + neurogranin + YKL-40 HC FTD 61.16 54.58 67.74 
p-tau + t-tau HC FTD 59.97 52.28 67.67 
Aβ1-42 + p-tau + neurogranin HC FTD 59.36 52.58 66.14 
 
Aβ1-42 + NFL MCI ADD 71.01 67.21 74.81 
Aβ1-42 + t-tau MCI ADD 70.97 67.19 74.75 
Aβ1-42 + t-tau + NFL MCI ADD 70.46 66.71 74.21 
Aβ1-42 + t-tau + neurogranin MCI ADD 69.89 66.17 73.61 
t-tau MCI ADD 69.27 65.38 73.16 
Aβ1-42 + t-tau + NFL + YKL40 MCI ADD 69.09 65.31 72.86 
Aβ1-42 + t-tau + YKL40 MCI ADD 69.08 65.24 72.91 
Aβ1-42 + p-tau + t-tau MCI ADD 69.05 65.21 72.89 
t-tau + YKL40 MCI ADD 68.90 65.07 72.73 
Aβ1-42 + NFL + YKL40 MCI ADD 68.76 64.90 72.62 
 
t-tau ADD FTD 82.23 78.47 85.99 
Aβ1-42 + p-tau + YKL-40 ADD FTD 81.30 77.22 85.37 
p-tau + t-tau ADD FTD 80.92 77.02 84.82 
Aβ1-42 + p-tau + t-tau ADD FTD 80.28 75.98 84.59 
Aβ1-42 + p-tau ADD FTD 80.28 75.85 84.70 
Aβ1-42 + neurogranin + YKL-40 ADD FTD 80.20 75.10 85.29 
Aβ1-42 + t-tau ADD FTD 80.10 75.89 84.32 
Aβ1-42 + p-tau + NFL ADD FTD 79.60 75.01 84.19 
t-tau + NFL ADD FTD 79.59 75.49 83.69 
Aβ1-42 + p-tau + t-tau + YKL-40 ADD FTD 79.56 75.34 83.78 
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Abbreviations: Aβ1-42, 42-amino acid-long amyloid beta peptide; ADD, Alzheimer’s disease dementia; AUROC, area under the receiver operating characteristic 
curve; C.I., confidence intervals; CSF, cerebrospinal fluid; FTD, frontotemporal dementia; HC, cognitively healthy controls; MCI, mild cognitive impairment; 
NFL, neurofilament light chain protein; p-tau, hyperphosphorylated tau; t-tau, total tau. NOTE. The AUROC curves result from fitting a logistic regression model 
within a 10-fold cross validation scheme to biomarkers data adjusted for age, sex, and site. 
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Table 3. Correlations between cerebrospinal fluid biomarkers in the study cohort. 
 
 p-tau t-tau NFL YKL-40 Neurogranin 
Aβ1-42 -0.305* -0.339** -0.180 0.002 -0.171 
p-tau  0.900*** 0.461*** 0.574*** 0.808*** 
t-tau   0.553*** 0.554*** 0.830*** 
NFL    0.619*** 0.387*** 
YKL-40     0.539*** 
*P ≤ 0.05 
**P ≤ 0.01 
***P ≤ 0.001 
Data are derived from Spearman’s rank-order correlation test after adjusting for age, sex, and site. P-values were 
corrected for multiple comparisons.  
Abbreviations: Aβ1-42, 42-amino acid-long amyloid beta peptide; NFL, neurofilament light chain protein; p-tau, 
hyperphosphorylated tau; t-tau, total tau.  
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FIGURE CAPTIONS 
Figure 1. CSF NFL, neurogranin, and YKL-40 concentrations according to diagnostic 
categories.  
Boxplots showing the CSF concentrations of (A) NFL, (B) neurogranin, and (C) YKL-40 
(adjusted for sex, age, and site) in ADD patients, FTD patients, MCI subjects, and cognitively HC. 
The lower, upper, and middle lines correspond to the 25th centile, 75th centile, and median, 
respectively. The whiskers extend to the minimum and maximum data points for NFL, neurogranin, 
and YKL-40. Dark circles represent outliers. Groupwise comparisons of NFL, neurogranin, and 
YKL-40 values (adjusted for sex, age, and site) were conducted through nonparametric Kruskal-
Wallis tests followed by pairwise comparison (Conover’s-test for multiple comparisons).  
 
Abbreviations: ADD, Alzheimer’s disease dementia; CSF, cerebrospinal fluid; FTD, 
frontotemporal dementia; HC, healthy controls; MCI, mild cognitive impairment; NFL, 
neurofilament light chain.  
 
Figure 2. Diagnostic workflow for the selection of the best performing biomarker 
combinations.  
